inVibe’s Labs Introduces TrialPulse
inVibe’s Labs introduces TrialPulse, a technology platform that helps integrate patient insights within the drug development process.
TrialPulse brings patient insights to clinical teams across six important areas, including the patient experience, disease burden, unmet needs, trial design, recruitment, and retention optimization. The innovative market research platform works by virtually recruiting a sample of real patients similar to the study's inclusion/exclusion criteria, then providing them with relevant stimuli (e.g., protocol summaries, e-consent forms, recruitment materials), and prompting them to provide candid feedback via inVibe's proprietary automated voice response (AVR) interview platform.
TrialPulse works by collecting all of the patient voice data, then analyzing it with a combination of human linguistic expertise and advanced machine learning technology, explained by this video. The interactive, searchable, filterable online portal enables our clients to listen to the actual voice responses, share audio clips with other team members and researchers, and/or simply review the high-level executive summary and visual reports created by inVibe analysts.
More on TrailPulse
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.
